H. Earp

发表

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

C. Perou, R. Millikan, T. Nielsen, 2006, JAMA.

Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status

S. Frye, B. Hendriks, P. Harari, 2015, Molecular Cancer Therapeutics.

Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC

D. Hayes, M. Wilkerson, M. Gulley, 2015, PloS one.

HER 4 D-Box Sequences Regulate Mitotic Progression and Degradation of the Nuclear HER 4 Cleavage Product s 80 HER 4

Melissa A. Sandahl, H. Earp, M. Sandahl, 2007 .

HER4 D-box sequences regulate mitotic progression and degradation of the nuclear HER4 cleavage product s80HER4.

Melissa A. Sandahl, H. Earp, M. Sandahl, 2007, Cancer research.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

C. Miller, S. Frye, A. Tan, 2013, The Journal of clinical investigation.

Discovery of Macrocyclic Pyrimidines as MerTK‐Specific Inhibitors

S. Frye, M. Machius, M. Miley, 2017, ChemMedChem.

UNC1062, a new and potent Mer inhibitor.

S. Frye, W. Janzen, H. Earp, 2013, European journal of medicinal chemistry.

Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.

S. Frye, W. Janzen, M. Machius, 2013, Journal of medicinal chemistry.

The EGF receptor family--multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4.

B. Calvo, H. Earp, C. Sartor, 2003, Transactions of the American Clinical and Climatological Association.

Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk

James Y. Dai, Jack A. Taylor, W. Willett, 2020, Journal of the National Cancer Institute.

MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.

Melissa A. Sandahl, Kristen M. Jacobsen, H. Earp, 2013, The Journal of clinical investigation.

Epidemiology of basal-like breast cancer

C. Perou, R. Millikan, L. Carey, 2008, Breast Cancer Research and Treatment.

MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non–small Cell Lung Cancers Expressing Wild-type EGFR Family Members

S. Frye, H. Earp, Xiaodong Wang, 2018, Clinical Cancer Research.

UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models

Kristen M. Jacobsen, S. Frye, J. Tyner, 2016, Clinical Cancer Research.

MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer

S. Frye, T. Owonikoko, S. Ramalingam, 2022, The Journal of clinical investigation.

A cryptic transactivation domain of EZH2 binds AR and AR’s splice variant, promoting oncogene activation and tumorous transformation

G. Wang, H. Earp, Ling Cai, 2022, bioRxiv.

MerTK as a therapeutic target in glioblastoma

C. Miller, M. Gilbert, S. Frye, 2018, Neuro-oncology.

Epidemiology of basal-like breast cancer

C. Perou, R. Millikan, L. Carey, 2008, Breast Cancer Research and Treatment.

Epithelial cell-directed efferocytosis in the post-partum mammary gland is necessary for tissue homeostasis and future lactation

Melissa A. Sandahl, H. Earp, M. Sandahl, 2010, BMC Developmental Biology.

MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.

Kristen M. Jacobsen, S. Frye, H. Earp, 2018, JCI insight.

Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays

D. Hayes, J. Parker, E. Papaemmanuil, 2018, Clinical Cancer Research.

Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features

S. Cole, C. Perou, A. Olshan, 2020, JNCI cancer spectrum.

Integrating Biology and Access to Care in Addressing Breast Cancer Disparities: 25 Years’ Research Experience in the Carolina Breast Cancer Study

A. Olshan, L. Carey, M. Troester, 2020, Current Breast Cancer Reports.

Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications

C. Perou, A. Olshan, L. Carey, 2019, Breast Cancer Research and Treatment.

Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study

Zhiyuan Hu, Charles M Perou, Andrew F Olshan, 2018, Journal of the National Cancer Institute.

The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma

David L. Marron, D. Hayes, K. Hoadley, 2019, Front. Oncol..

Enhancing Next‐Generation Sequencing‐Guided Cancer Care Through Cognitive Computing

Laxmi Parida, Erhan Bilal, Raquel Norel, 2017, The oncologist.

Cloning and developmental expression analysis of the murine c-mer tyrosine kinase.

H. Snodgrass, W. Stanford, H. Earp, 1995, Oncogene.

Cloning and Mrna Expression Analysis of a Novel Human Protooncogene, C-merr

H. Snodgrass, H. Earp, D. Graham, 2022 .

Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.

J. Mohler, Y. Whang, H. Earp, 2005, Cancer research.

ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer.

D. Zheng, A. Sboner, J. Parker, 2018, Molecular cell.

Targeting the TAM Receptors in Leukemia

H. Earp, H. Earp, D. DeRyckere, 2016, Cancers.

TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.

H. Earp, D. Graham, H Shelton Earp, 2008, Advances in cancer research.

Interaction between androgen receptor and coregulator SLIRP is regulated by Ack1 tyrosine kinase and androgen

J. Parker, G. Wang, Y. Whang, 2019, Scientific Reports.

Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation

J. Mohler, Y. Whang, H. Earp, 2007, Proceedings of the National Academy of Sciences.

OP-IJEJ190194 1..15

Katja, James Y. Dai, Marike, 2019 .

Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox.

James L Mohler, J. Mohler, Y. Whang, 2005, Cancer research.

Mutation of Androgen Receptor N-Terminal Phosphorylation Site Tyr-267 Leads to Inhibition of Nuclear Translocation and DNA Binding

Joel S. Parker, J. Parker, Y. Whang, 2015, PloS one.

Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia

S. Frye, J. Tyner, H. Earp, 2021, Cancers.

Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell Growth

F. S. French, Y. Whang, E. Wilson, 2005, Clinical Cancer Research.

Human epidermal receptor-2 expression in prostate cancer.

M. Iacocca, L. Caskey, B. Calvo, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer

H. Earp, D. DeRyckere, D. Graham, 2021, Cancers.

LYMPHOID NEOPLASIA Mer receptor tyrosine kinase is a therapeutic target in pre – B-cell acute lymphoblastic leukemia

Kristen M. Jacobsen, A. Tan, H. Earp, 2013 .

Keypoints

Kristen M. Jacobsen, A. Tan, H. Earp, 2019, Encyclopedia of Biometrics.

Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia

H. Earp, S. Hunsucker, H. Martinson, 2013, Oncogene.

Abstract 240: MERTK inhibition induces an anti-leukemia dendritic cell - T cell axis while TYRO3 inhibition protects through a separate mechanism

S. Frye, Xiaodong Wang, H. Earp, 2022, Cancer Research.

Ectopic Expression of the Proto-oncogene Mer in Pediatric T-Cell Acute Lymphoblastic Leukemia

H. Snodgrass, M. Schell, J. Kurtzberg, 2006, Clinical Cancer Research.

MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression

C. Fan, C. Perou, N. Dokholyan, 2019, Nature Communications.

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.

James S. Duncan, Steven P. Angus, C. Perou, 2017, Cancer discovery.

Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors

H. Earp, D. Graham, A. Keating, 2010, Expert opinion on therapeutic targets.

ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.

C. Perou, K. Hutchinson, J. Balko, 2013, The Journal of clinical investigation.

Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia

H. Earp, S. Hunsucker, H. Martinson, 2013, Oncogene.

Inherited predisposition to breast cancer in the Carolina Breast Cancer Study

T. Walsh, M. King, C. Perou, 2021, NPJ breast cancer.

Germline Analysis from Tumor–Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings

Lisle E. Mose, D. Hayes, J. Parker, 2016, Clinical Cancer Research.

YY1 cistrome analysis uncovers an essential requirement of the YY1:BRD4-PFKP regulatory axis for promoting tumorigenesis of castration-resistant prostate cancer

Aaron J. Storey, D. Zheng, J. Parker, 2020, bioRxiv.

Inherited predisposition to breast cancer in the Carolina Breast Cancer Study

T. Walsh, M. King, C. Perou, 2021, npj Breast Cancer.

Prolactin and ErbB4/HER4 signaling interact via Janus kinase 2 to induce mammary epithelial cell gene expression differentiation.

Melissa A. Sandahl, H. Earp, M. Sandahl, 2008, Molecular endocrinology.

ErbB4 Splice Variants Cyt1 and Cyt2 Differ by 16 Amino Acids and Exert Opposing Effects on the Mammary Epithelium In Vivo

Melissa A. Sandahl, L. Chodosh, H. Earp, 2009, Molecular and Cellular Biology.

ErbB4/HER4: Role in Mammary Gland Development, Differentiation and Growth Inhibition

H. Earp, S. Feng, K. E. Strunk, 2008, Journal of Mammary Gland Biology and Neoplasia.

Heregulin-Dependent Delay in Mitotic Progression Requires HER4 and BRCA1

Melissa A. Sandahl, L. Caskey, K. Cowan, 2006, Molecular and Cellular Biology.

FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036

Michael L. Gatza, C. Fan, C. Perou, 2021, NPJ breast cancer.

MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme

S. Frye, M. Varella‐Garcia, J. Kowalski, 2016, PloS one.

Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer

K. Davies, H. Earp, C. Cummings, 2014, OncoTarget.

Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors.

S. Frye, W. Janzen, M. Machius, 2013, Journal of medicinal chemistry.

Molecular Pathways Molecular Pathways : MERTK Signaling in Cancer

H. Earp, C. Cummings, D. DeRyckere, 2013 .

Molecular Pathways Molecular Pathways : MERTK Signaling in Cancer

H. Earp, C. Cummings, D. DeRyckere, 2013 .

The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells

H. Earp, C. Husted, L. Miraglia, 2005, Breast Cancer Research.

Cistrome analysis of YY1 uncovers a regulatory axis of YY1:BRD2/4-PFKP during tumorigenesis of advanced prostate cancer

Aaron J. Storey, D. Zheng, J. Parker, 2021, Nucleic acids research.

Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis.

Jeffery M. Meyer, Jack A. Taylor, A. Whittemore, 2018, International journal of epidemiology.

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases

Daniel Gioeli, Y. Whang, M. Karaca, 2010, Oncogene.

Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment

S. Frye, H. Earp, Xiaodong Wang, 2023, Frontiers in Immunology.

Bone Marrow Stromal Cell Mediated Resistance to Mertk Inhibition in Acute Leukemia

S. Frye, H. Earp, A. Hill, 2016 .

Abstract 1736: A novel Mer tyrosine kinase inhibitor mediates increased cell killing in combination with FGFR inhibition

S. Frye, T. P. Newton, H. Earp, 2014 .

Integrating access to care and tumor patterns by race and age in the Carolina Breast Cancer Study, 2008–2013

A. Olshan, A. Aiello, M. Troester, 2020, Cancer Causes & Control.

UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo

S. Frye, W. Janzen, H. Earp, 2013, Molecular Cancer Therapeutics.

Factor XIIIA—expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking

D. Hayes, M. Wilkerson, V. Godfrey, 2018, Nature Communications.

The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer

K. Davies, H. Earp, H. Earp, 2014, Nature Reviews Cancer.

The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.

S. Frye, H. Earp, C. Jordan, 2016, JCI insight.

Abstract 947: A small molecule Mer tyrosine kinase inhibitor (UNC MerTKi) effectively inhibits growth of murine melanoma

David B. Darr, N. Sharpless, S. Frye, 2014 .

Abstract 1740: Development of a novel small molecule MER tyrosine kinase inhibitor with therapeutic activity in cell culture and mouse models of acute lymphoblastic leukemia

S. Frye, W. Janzen, H. Earp, 2014 .

Edinburgh Research Explorer Assessment of interactions between 205 breast cancer susceptibility loci and 13 established risk factors in relation to breast cancer risk in the Breast Cancer Association Consortium

Katja, James Y. Dai, Marike, 2019 .

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

N. Popitsch, H. Kohrt, R. Sullivan, 2013, Clinical Cancer Research.

Validation of Breast Cancer PAM50 Intrinsic Subtypes by Gene Expression Microarray in a Clinical Laboratory

C. Perou, M. Gulley, Zhiyuan Hu, 2013 .

HER4 Mediates Ligand-Dependent Antiproliferative and Differentiation Responses in Human Breast Cancer Cells

L. Caskey, B. Calvo, N. Hynes, 2001, Molecular and Cellular Biology.

Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.

H. Earp, H. Earp, C. Sartor, 2004, International journal of radiation oncology, biology, physics.

TAM family kinases as therapeutic targets at the interface of cancer and immunity

H. Earp, D. DeRyckere, D. Graham, 2023, Nature Reviews Clinical Oncology.

UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor

D. Newton, S. Frye, W. Janzen, 2014, Journal of medicinal chemistry.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

C. Miller, S. Frye, J. M. Shields, 2013, The Journal of clinical investigation.

UNC 569 , a novel small molecule Mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo

S. Frye, W. Janzen, H. Earp, 2013 .

The small‐molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis

S. Frye, X. Wang, H. Earp, 2018, Journal of thrombosis and haemostasis : JTH.

ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer.

D. Zheng, A. Sboner, G. Wang, 2018, Molecular cell.

ZFX mediates non-canonical oncogenic functions of the androgen receptor splice variant 7 (AR-V7) in castrate-resistant prostate cancer

A. Sboner, H. Earp, Ping Wang, 2018 .

Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia

S. Frye, H. Earp, A. Hill, 2015, Oncotarget.

Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma

S. Frye, Carolina P. Lin, H. Earp, 2019, Proceedings of the National Academy of Sciences.

MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.

Melissa A. Sandahl, Kristen M. Jacobsen, H. Earp, 2013, The Journal of clinical investigation.

Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.

S. Frye, M. Machius, M. Miley, 2013, Journal of medicinal chemistry.

Discovery of Macrocyclic Pyrimidines as MerTK‐Specific Inhibitors

S. Frye, M. Machius, M. Miley, 2017, ChemMedChem.

Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma

S. Frye, S. Eckhardt, J. Tentler, 2018, Molecular Cancer Therapeutics.

TITLE: Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma

S. Frye, Xiaodong Wang, S. Eckhardt, 2018 .

Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia.

S. Frye, W. Janzen, M. Machius, 2012, ACS medicinal chemistry letters.

The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells.

Melissa A. Sandahl, H. Earp, K. Elenius, 2006, Molecular biology of the cell.

Erratum: Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia

H. Earp, S. Hunsucker, D. DeRyckere, 2016, Oncogene.